| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Clinical Investigations |
Palo Alto Veterans Administration Hospital and Stanford University Medical Center, Palo Alto, California 94305 [T. R., D. S.]; Mayo Clinic, Rochester, Minnesota 55905 [E. G., J. An., J. R.]; M.D. Anderson Cancer Center, Houston, Texas [J. Ab.]; Massachusetts Institute of Technology, Cambridge, Massachusetts 02138 [L. M. W.]; Onyx Pharmaceuticals, Richmond, California 94806 [B. R., C. H., M. H., L. R., D. K.]; and Pfizer Corporation, Ann Arbor, Michigan 48103 [M. U.]
Replication-selective oncolytic adenoviruses are being developed for the treatment of cancer, but the safety and feasibility of repeated adenovirus delivery to tumors via the bloodstream was unknown, particularly in light of a patient death after hepatic artery infusion of a replication-defective adenovirus vector. We performed a Phase II trial of an oncolytic replication-selective adenovirus (dl1520, also known as Onyx-015) administered by hepatic artery infusion in patients with gastrointestinal carcinoma metastatic to the liver (n = 27). dl1520 was infused into the hepatic artery (2 x 1012 particles) on days 1 and 8 as a single agent, and thereafter starting on day 22 in combination with i.v. 5-fluorouracil and leucovorin every 28 days. Repeated viral infusions were feasible, and no deaths occurred on study; reversible grade 3/4 hyperbilirubinemia occurred in 2 patients. Systemic inflammatory cytokine responses varied greatly between patients and even between cycles within a given patient. Proinflammatory cytokines [e.g., tumor necrosis factor, IFN-
, and interleukin (IL) 6] typically rose within 3 h and were followed at 18 h by a rise in IL-10. However, in the single patient who suffered a severe but reversible systemic inflammatory response, a unique cytokine profile was detected: marked acute increases of IL-6 (20-fold higher than average for all of the patients) and inhibition of IL-10 production. Delayed secondary peaks of viremia were reproducibly detected 3–6 days after treatment, even in the presence of high level neutralizing antibody titers and antiviral cytokines. Mathematical modeling was used to calculate the number of virus particles produced and shed into the blood with each replication cycle. The combination of virotherapy and chemotherapy had antitumoral activity in some chemotherapy-resistant colorectal tumors. The intra-arterial infusion of oncolytic adenoviruses warrants additional study.
This article has been cited by other articles:
|
|
 |
|
  A. N. Blackford and R. J. A. Grand Adenovirus E1B 55-Kilodalton Protein: Multiple Roles in Viral Infection and Cell Transformation J. Virol., May 1, 2009; 83(9): 4000 - 4012. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Nakagawa, H. Tanaka, T. Shirakawa, A. Gotoh, Y. Hayashi, K. Hamada, M. Tsukuda, and K.-i. Nibu Cyclooxygenase 2 Promoter-Based Replication-Selective Adenoviral Vector for Hypopharyngeal Cancer Arch Otolaryngol Head Neck Surg, March 1, 2009; 135(3): 282 - 286. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Gomes, M. S. Rodrigues, A. P. Phadke, L. D. Butcher, C. Starling, S. Chen, D. Chang, R. Hernandez-Alcoceba, J. T. Newman, M. J. Stone, et al. Antitumor Activity of an Oncolytic Adenoviral-CD40 Ligand (CD154) Transgene Construct in Human Breast Cancer Cells Clin. Cancer Res., February 15, 2009; 15(4): 1317 - 1325. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Huang, L. Zhuang, Y. Cao, Q. Gao, Z. Han, D. Tang, H. Xing, W. Wang, Y. Lu, G. Xu, et al. Biodistribution and kinetics of the novel selective oncolytic adenovirus M1 after systemic administration Mol. Cancer Ther., June 1, 2008; 7(6): 1624 - 1632. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Li, J. Zhou, D. Weng, C. Zhang, L. Li, B. Wang, Y. Song, Q. He, D. Lin, D. Chen, et al. Adjuvant Adenovirus-Mediated Delivery of Herpes Simplex Virus Thymidine Kinase Administration Improves Outcome of Liver Transplantation in Patients with Advanced Hepatocellular Carcinoma Clin. Cancer Res., October 1, 2007; 13(19): 5847 - 5854. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Hiraoka, T. Kimura, C. R. Logg, C.-K. Tai, K. Haga, G. W. Lawson, and N. Kasahara Therapeutic Efficacy of Replication-Competent Retrovirus Vector-Mediated Suicide Gene Therapy in a Multifocal Colorectal Cancer Metastasis Model Cancer Res., June 1, 2007; 67(11): 5345 - 5353. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Schepelmann, L. M. Ogilvie, D. Hedley, F. Friedlos, J. Martin, I. Scanlon, P. Chen, R. Marais, and C. J. Springer Suicide Gene Therapy of Human Colon Carcinoma Xenografts Using an Armed Oncolytic Adenovirus Expressing Carboxypeptidase G2 Cancer Res., May 15, 2007; 67(10): 4949 - 4955. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Koizumi, T. Yamaguchi, K. Kawabata, F. Sakurai, T. Sasaki, Y. Watanabe, T. Hayakawa, and H. Mizuguchi Fiber-Modified Adenovirus Vectors Decrease Liver Toxicity through Reduced IL-6 Production J. Immunol., February 1, 2007; 178(3): 1767 - 1773. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hiraoka, T. Kimura, C. R. Logg, and N. Kasahara Tumor-Selective Gene Expression in a Hepatic Metastasis Model after Locoregional Delivery of a Replication-Competent Retrovirus Vector Clin. Cancer Res., December 1, 2006; 12(23): 7108 - 7116. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C.C. Hu, R. S. Coffin, C. J. Davis, N. J. Graham, N. Groves, P. J. Guest, K. J. Harrington, N. D. James, C. A. Love, I. McNeish, et al. A Phase I Study of OncoVEXGM-CSF, a Second-Generation Oncolytic Herpes Simplex Virus Expressing Granulocyte Macrophage Colony-Stimulating Factor. Clin. Cancer Res., November 15, 2006; 12(22): 6737 - 6747. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Sinha, G. J. Kim, S. Nie, and D. M. Shin Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol. Cancer Ther., August 1, 2006; 5(8): 1909 - 1917. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J.V. Vaha-Koskela, J. P. Kallio, L. C. Jansson, J. E. Heikkila, V. A. Zakhartchenko, M. A. Kallajoki, V.-M. Kahari, and A. E. Hinkkanen Oncolytic capacity of attenuated replicative semliki forest virus in human melanoma xenografts in severe combined immunodeficient mice. Cancer Res., July 15, 2006; 66(14): 7185 - 7194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Laurie, J. C. Bell, H. L. Atkins, J. Roach, M. K. Bamat, J. D. O'Neil, M. S. Roberts, W. S. Groene, and R. M. Lorence A Phase 1 Clinical Study of Intravenous Administration of PV701, an Oncolytic Virus, Using Two-Step Desensitization Clin. Cancer Res., April 15, 2006; 12(8): 2555 - 2562. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Izawa, K. Sano, M. Takehara, M. Inobe, J.-i. Suzuki, H. Imamura, M. Takahashi, U. Ikeda, M. Isobe, and T. Uede Cre/loxP-mediated CTLA4IgG gene transfer induces clinically relevant immunosuppression via on-off gene recombination in vivo Cardiovasc Res, January 1, 2006; 69(1): 289 - 297. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kambara, Y. Saeki, and E. A. Chiocca Cyclophosphamide Allows for In vivo Dose Reduction of a Potent Oncolytic Virus Cancer Res., December 15, 2005; 65(24): 11255 - 11258. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Zhou, Q. Gao, G. Chen, X. Huang, Y. Lu, K. Li, D. Xie, L. Zhuang, J. Deng, and D. Ma Novel Oncolytic Adenovirus Selectively Targets Tumor-Associated Polo-Like Kinase 1 and Tumor Cell Viability Clin. Cancer Res., December 1, 2005; 11(23): 8431 - 8440. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Shinozaki, O. Ebert, A. Suriawinata, S. N. Thung, and S. L. C. Woo Prophylactic Alpha Interferon Treatment Increases the Therapeutic Index of Oncolytic Vesicular Stomatitis Virus Virotherapy for Advanced Hepatocellular Carcinoma in Immune-Competent Rats J. Virol., November 1, 2005; 79(21): 13705 - 13713. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Wirth, F. Kuhnel, B. Fleischmann-Mundt, N. Woller, M. Djojosubroto, K. L. Rudolph, M. Manns, L. Zender, and S. Kubicka Telomerase-Dependent Virotherapy Overcomes Resistance of Hepatocellular Carcinomas against Chemotherapy and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand by Elimination of Mcl-1 Cancer Res., August 15, 2005; 65(16): 7393 - 7402. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Schepelmann, P. Hallenbeck, L. M. Ogilvie, D. Hedley, F. Friedlos, J. Martin, I. Scanlon, C. Hay, L. K. Hawkins, R. Marais, et al. Systemic Gene-Directed Enzyme Prodrug Therapy of Hepatocellular Carcinoma Using a Targeted Adenovirus Armed with Carboxypeptidase G2 Cancer Res., June 15, 2005; 65(12): 5003 - 5008. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Shayakhmetov, Z.-Y. Li, S. Ni, and A. Lieber Interference with the IL-1-Signaling Pathway Improves the Toxicity Profile of Systemically Applied Adenovirus Vectors J. Immunol., June 1, 2005; 174(11): 7310 - 7319. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kambara, H. Okano, E. A. Chiocca, and Y. Saeki An Oncolytic HSV-1 Mutant Expressing ICP34.5 under Control of a Nestin Promoter Increases Survival of Animals even when Symptomatic from a Brain Tumor Cancer Res., April 1, 2005; 65(7): 2832 - 2839. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. Thorne, G. Brooks, Y.-L. Lee, T. Au, L. F. Eng, and T. Reid Effects of Febrile Temperature on Adenoviral Infection and Replication: Implications for Viral Therapy of Cancer J. Virol., January 1, 2005; 79(1): 581 - 591. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Tsai, D. E. Johnson, A. Rahman, S. F. Wen, D. LaFace, J. Philopena, J. Nery, M. Zepeda, D. C. Maneval, G. W. Demers, et al. Impact of Human Neutralizing Antibodies on Antitumor Efficacy of an Oncolytic Adenovirus in a Murine Model Clin. Cancer Res., November 1, 2004; 10(21): 7199 - 7206. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Chu, D. E. Post, F. R. Khuri, and E. G. Van Meir Use of Replicating Oncolytic Adenoviruses in Combination Therapy for Cancer Clin. Cancer Res., August 15, 2004; 10(16): 5299 - 5312. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N R Lemoine and I A McNeish Gene transfer: Bax to the future for cancer therapy Gut, April 1, 2004; 53(4): 478 - 479. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Barzon, M. Boscaro, and G. Palu Endocrine Aspects of Cancer Gene Therapy Endocr. Rev., February 1, 2004; 25(1): 1 - 44. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. A. Lanson Jr., P. L. Friedlander, P. Schwarzenberger, J. K. Kolls, and G. Wang Replication of an Adenoviral Vector Controlled by the Human Telomerase Reverse Transcriptase Promoter Causes Tumor-Selective Tumor Lysis Cancer Res., November 15, 2003; 63(22): 7936 - 7941. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Moon, Y. Oh, and J. A. Roth Current Status of Gene Therapy for Lung Cancer and Head and Neck Cancer Clin. Cancer Res., November 1, 2003; 9(14): 5055 - 5067. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Portella, R. Pacelli, S. Libertini, L. Cella, G. Vecchio, M. Salvatore, and A. Fusco ONYX-015 Enhances Radiation-Induced Death of Human Anaplastic Thyroid Carcinoma Cells J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 5027 - 5032. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
